Analysts expect Esperion Therapeutics (NASDAQ:ESPR) to post ($1.56) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Esperion Therapeutics’ earnings, with estimates ranging from ($1.96) to ($1.29). Esperion Therapeutics posted earnings of ($1.80) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 13.3%. The firm is expected to announce its next earnings results on Thursday, May 3rd.
On average, analysts expect that Esperion Therapeutics will report full year earnings of ($5.61) per share for the current fiscal year, with EPS estimates ranging from ($6.58) to ($4.44). For the next fiscal year, analysts forecast that the firm will report earnings of ($5.50) per share, with EPS estimates ranging from ($6.74) to ($4.54). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that that provide coverage for Esperion Therapeutics.
Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported ($1.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.80) by $0.36. During the same quarter in the prior year, the business earned ($1.29) earnings per share.
ESPR has been the topic of a number of recent research reports. BidaskClub lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, March 20th. Citigroup lowered shares of Esperion Therapeutics from a “buy” rating to a “neutral” rating and raised their price objective for the company from $77.00 to $96.00 in a research note on Monday, January 22nd. Northland Securities raised their price objective on shares of Esperion Therapeutics from $100.00 to $121.00 and gave the company a “buy” rating in a research note on Thursday. UBS set a $88.00 price objective on shares of Esperion Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 17th. Finally, Chardan Capital raised their price objective on shares of Esperion Therapeutics from $75.00 to $100.00 and gave the company a “neutral” rating in a research note on Tuesday, March 27th. Six analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $96.31.
In related news, Director Nicole Vitullo sold 11,674 shares of the firm’s stock in a transaction dated Thursday, January 25th. The shares were sold at an average price of $71.79, for a total transaction of $838,076.46. Following the completion of the sale, the director now owns 3,177 shares in the company, valued at $228,076.83. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Roger S. Newton sold 25,000 shares of the firm’s stock in a transaction dated Thursday, March 29th. The stock was sold at an average price of $72.37, for a total transaction of $1,809,250.00. Following the sale, the director now owns 639,682 shares of the company’s stock, valued at approximately $46,293,786.34. The disclosure for this sale can be found here. Corporate insiders own 32.50% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Raymond James Financial Services Advisors Inc. purchased a new stake in Esperion Therapeutics during the fourth quarter worth about $222,000. BB&T Securities LLC purchased a new stake in Esperion Therapeutics during the fourth quarter worth about $263,000. First Mercantile Trust Co. increased its holdings in Esperion Therapeutics by 56.0% during the fourth quarter. First Mercantile Trust Co. now owns 4,233 shares of the biopharmaceutical company’s stock worth $279,000 after buying an additional 1,519 shares during the last quarter. Creative Planning purchased a new stake in Esperion Therapeutics during the fourth quarter worth about $314,000. Finally, Oakmont Partners LLC purchased a new stake in Esperion Therapeutics during the fourth quarter worth about $323,000. Institutional investors and hedge funds own 91.66% of the company’s stock.
Shares of Esperion Therapeutics stock traded down $0.47 during trading hours on Friday, reaching $73.69. The company’s stock had a trading volume of 293,749 shares, compared to its average volume of 618,476. Esperion Therapeutics has a one year low of $30.95 and a one year high of $82.68. The firm has a market capitalization of $2,005.30, a price-to-earnings ratio of -10.68 and a beta of 2.51.
COPYRIGHT VIOLATION NOTICE: “Esperion Therapeutics (ESPR) Expected to Post Earnings of -$1.56 Per Share” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/04/20/esperion-therapeutics-espr-expected-to-post-earnings-of-1-56-per-share.html.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Get a free copy of the Zacks research report on Esperion Therapeutics (ESPR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.